Flerie AB Reports Positive ATR-258 PoM Results; Plans Phase 2 in 2027
Flerie AB announced that its portfolio company Atrogi reported positive proof-of-mechanism data for ATR-258 in a study involving 13 overweight or obese individuals. The study showed improved physical function, increased lean mass, and reduced fat mass. Phase 2 trials are planned for 2027.